Logotype for Natera Inc

Natera (NTRA) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Natera Inc

Q3 2026 earnings summary

6 Nov, 2026

Executive summary

  • Q3 revenue was $794.0M, up 34.1% YoY; total tests processed reached 1.093M, up 22.3%, and clinical MRD oncology units were ~316K, up >56%.

  • FY2026 revenue guidance rose to $3.005B-$3.035B, a $140M midpoint increase; the 2029 revenue target is $6B.

  • Net loss narrowed to $59.9M, or $0.42 per diluted share, from $87.5M, or $0.64, in Q3 2025.

  • Growth reflected higher test volumes and ASP improvements, while R&D, lab expansion and commercialization spending weighed on profitability.

Financial highlights

  • Q3 revenue was $794.0M versus $592.2M a year earlier; revenue excluding true-ups grew ~42% YoY.

  • Q3 gross profit was $513.5M and GAAP gross margin was 64.7%, versus 64.9% YoY; margin excluding true-ups was 63.2%.

  • Q3 operating expenses were $862.3M, up 25.0% YoY; R&D was $242.4M and SG&A was $333.7M.

  • Nine-month revenue was $2.243B versus $1.641B; net loss narrowed to $212.0M from $255.4M.

Outlook and guidance

  • FY2026 revenue guidance increased to $3.005B-$3.035B from $2.850B-$2.910B; assumptions include continued volume growth and exclude true-ups.

  • FY2026 gross-margin guidance is 64%-66%; SG&A guidance is $1.225B-$1.300B and R&D guidance is $825M-$925M.

  • 2027 preliminary outlook assumes unit growth comparable to 2026, relatively steady ASPs, gross margin within the FY2026 guide range and OPEX growth of 10%-12%.

  • The 2029 revenue target is $6B, supported by oncology growth, global expansion, pharma and data licensing, and continued growth in other areas.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Natera